Drug Delivery

GLOBAL DELIVERY MARKET – Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier

Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.

NANOTECHNOLOGY MARKET – Nanotechnology Markets in Healthcare & Medicine

Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.

FORMULATION DEVELOPMENT – Solumerized(TM) Trans-Resveratrol, Bridging the Bioenhancement Gap to Drug Delivery Between Pharmaceuticals & Dietary Supplements

Amir Zalcenstein, PhD, Galia Temtsin Krayz, PhD, and Sabina Glozman, PhD, discuss the example of Resveratrol, a supplement with a solid body of scientific data attesting to its efficacy in enhancing lifespan and treating a variety of medical conditions, which yet remains short of its true market potential due to stability, bioavailability, and cost issues.

EXCLUSIVE ONLINE CONTENT

6/10/2019

Aptar Acquires Nanopharm & Gateway Analytical

AptarGroup, Inc. recently announced it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million.

5/30/2019

Sol-Gel Technologies Announces Seventh Agreement

Sol-Gel Technologies, Ltd. recently announced it has entered into a seventh collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc for the development, manufacturing, and commercialization of two new generic formulations of antibiotic foams.

5/23/2019

Mercia Invests in Transdermal Drug Delivery Specialist

Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.